User login
Key clinical point: Dupilumab maintained efficacy against moderate-to-severe atopic dermatitis (AD) with no new safety signals over 104 weeks; however, it was ineffective in treating head-and-neck AD.
Major finding: The median Eczema Area and Severity Index score decreased significantly from 18.0 at baseline to 2.0 at week 52 and 1.7 at week 104 (both P < .0001); 35% of patients reported an adverse event, with conjunctivitis being the most common (25%). Although the 104-week treatment persistence rate was 86%, the majority of patients still had AD in the head-and-neck area.
Study details: This real-world study included 347 adult patients with moderate-to-severe AD who received dupilumab and were registered in the prospective Severe and ChRonic Atopic dermatitis Treatment CoHort (SCRATCH) registry during 2017-2022.
Disclosures: The SCRATCH registry was supported by research grants from Sanofi-Genzyme and Pfizer. Some authors reported ties with various organizations, including Sanofi-Genzyme and Pfizer.
Source: Vittrup I et al. A nationwide 104 weeks real-world study of dupilumab in adults with atopic dermatitis: Ineffectiveness in head-and-neck dermatitis. J Eur Acad Dermatol Venereol. 2023 (Jan 6). Doi: 10.1111/jdv.18849
Key clinical point: Dupilumab maintained efficacy against moderate-to-severe atopic dermatitis (AD) with no new safety signals over 104 weeks; however, it was ineffective in treating head-and-neck AD.
Major finding: The median Eczema Area and Severity Index score decreased significantly from 18.0 at baseline to 2.0 at week 52 and 1.7 at week 104 (both P < .0001); 35% of patients reported an adverse event, with conjunctivitis being the most common (25%). Although the 104-week treatment persistence rate was 86%, the majority of patients still had AD in the head-and-neck area.
Study details: This real-world study included 347 adult patients with moderate-to-severe AD who received dupilumab and were registered in the prospective Severe and ChRonic Atopic dermatitis Treatment CoHort (SCRATCH) registry during 2017-2022.
Disclosures: The SCRATCH registry was supported by research grants from Sanofi-Genzyme and Pfizer. Some authors reported ties with various organizations, including Sanofi-Genzyme and Pfizer.
Source: Vittrup I et al. A nationwide 104 weeks real-world study of dupilumab in adults with atopic dermatitis: Ineffectiveness in head-and-neck dermatitis. J Eur Acad Dermatol Venereol. 2023 (Jan 6). Doi: 10.1111/jdv.18849
Key clinical point: Dupilumab maintained efficacy against moderate-to-severe atopic dermatitis (AD) with no new safety signals over 104 weeks; however, it was ineffective in treating head-and-neck AD.
Major finding: The median Eczema Area and Severity Index score decreased significantly from 18.0 at baseline to 2.0 at week 52 and 1.7 at week 104 (both P < .0001); 35% of patients reported an adverse event, with conjunctivitis being the most common (25%). Although the 104-week treatment persistence rate was 86%, the majority of patients still had AD in the head-and-neck area.
Study details: This real-world study included 347 adult patients with moderate-to-severe AD who received dupilumab and were registered in the prospective Severe and ChRonic Atopic dermatitis Treatment CoHort (SCRATCH) registry during 2017-2022.
Disclosures: The SCRATCH registry was supported by research grants from Sanofi-Genzyme and Pfizer. Some authors reported ties with various organizations, including Sanofi-Genzyme and Pfizer.
Source: Vittrup I et al. A nationwide 104 weeks real-world study of dupilumab in adults with atopic dermatitis: Ineffectiveness in head-and-neck dermatitis. J Eur Acad Dermatol Venereol. 2023 (Jan 6). Doi: 10.1111/jdv.18849